Followers | 128 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Sunday, January 23, 2011 2:24:49 PM
A lot of MAJOR news coming very soon to push this GOLDMINE to ALL TIME HIGHS .
Market Cap: 34.6 MIL$
Price: 5.28 $
Shares Out: 6.5 MIL // 3 MIL Shares held by Insiders
Short Data : Only 3154 Shares
Upcoming Milestones for 1Q 2011 (New dates below are from the Company ,I got a response from IR yesterday )
http://www.wsw.com/webcast/maxim3/dsci/2__Slide21.JPG
Phase 2 results for Blockbuster Candidate DSC127 this Week or first Week in Feb 2011
Expect FDA 510k Clearance for Medihoney gel 4Q10 = VERY SOON
Submit another 510K Application to FDA for Medihoney Hydro in Jan or early Feb 2011
PartnerShip with upfront cash payment for Potential Blockbuster DSC127
**************************************************************
A MUST READ ..
http://www.ir.dermasciences.com/profiles/investor/fullpage.asp?f=1&BzID=1109&to=cp&Nav=0&LangID=1&s=302&ID=10208
KEY PRODUCT UNDER DEVELOPMENT
DSDSC127 (angiotensin analog)
Novel angiotensin analog for use in wound healing and scar reduction. Successfully completed a phase I trial in 4Q07, and presently undergoing phase II trials to assess safety and efficacy of DSC127 on healing diabetic ulcers. Results from the phase II trials are expected in 4Q10.
* "Blockbuster" potential - with applications in the following markets:
o $10 billion chronic wound market
o $8 billion scar prevention/reduction market
o $6 billion burn market
o $6 billion radiation and other wound markets
* Limited competition - Systagenix's Regranex is the only FDA-approved drug for wound healing. (Systegenix is formerly Johnson & Johnson's Chronic Wound Care division.)
o Regranex has a black box warning and has achieved sales exceeding $100M per year
*************************************************************
Derma Sciences presents a unique opportunity in the micro-cap biomed space since it has a core business focused on would care which generates revenue and operating cash flow to fund the Phase 2 clinical development for a treatment (DC127) that targets a prescription drug market that is about 5X the Company’s current market cap (based on Regranex sales of $150M). In addition, pre-clinical data suggests DC127 may offer both safety and efficacy advantages over Regranex and the licensing deal by Shire for a scar prevention treatment that included a $75M up-front payment suggests Derma Sciences has the potential to secure a licensing deal that could include an up-front cash payment in excess of its current market cap of around $30M.
**************************************************************
Watch Videos about their great Products !
http://www.ir.dermasciences.com/profiles/investor/fullpage.asp?f=1&BzID=1109&to=cp&Nav=0&LangID=1&s=302&ID=10309
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM